Physician profile
Aashesh Verma
NPI 1962815043
$1,894.35
in general payments reported to CMS, 2019-2025
16 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.77 · 2021: $188 · 2022: $226 · 2023: $387 · 2024: $631 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $16.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,445.55 |
| Education | $16.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $496.48 | 2021-2023 | Endoflip |
| Abbvie INC. | $396.79 | 2024-2025 | |
| Endogastric Solutions, INC | $374.19 | 2022-2024 | Esophyx |
| Takeda Pharmaceuticals U.S.A., INC. | $170.01 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $147.51 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $97.87 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $32.50 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $26.52 | 2025 | Iqirvo |
| Qol Medical, LLC | $25.48 | 2025 | Sucraid |
| Mirum Pharmaceuticals, INC. | $23.27 | 2025 | Livmarli |
| Novo Nordisk INC | $20.89 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $19.82 | 2023 | Suflave, Sutab |
| Capsovision, INC. | $19.05 | 2024 | Capsocam Plus |
| Pfizer INC. | $18.77 | 2020 | |
| Evoke Pharma, INC. | $13.46 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Balt USA, LLC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aashesh Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.